Online citations, reference lists, and bibliographies.
← Back to Search

Cardiac Toxicity In Cancer Survivors

D. Lenihan, S. Oliva, E. Chow, D. Cardinale
Published 2013 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Cardiac disease is a major concern for cancer survivors, and this can be manifested as cardiac dysfunction from myocardial damage, valvular disease, atherosclerosis, and/or pericardial disease. In this “dialogue” between select European and American investigators, present current perspectives (both similarities and differences) are presented regarding the diagnosis and management of cardiac disease among cancer survivors, with a focus on left ventricular (LV) systolic dysfunction and heart failure. The authors conclude that comprehensive cardiac risk assessment is necessary to optimally manage all cancer survivors, and the integration of common definitions is necessary. Ongoing and future research will need to incorporate cardiovascular management principles in the long‐term assessment of cancer survivors. Cardiac biomarkers, troponin, and the natriuretic peptides are becoming essential in the management of cardiac disease in cancer survivors coupled with periodic use of sophisticated imaging tools. Recognition of specific cancer therapy and the increased cardiovascular risk is an ongoing task that will remain of paramount importance for optimal outcomes among cancer survivors. Cancer 2013;119(11 suppl):2131‐42. © 2013 American Cancer Society.
This paper references
10.1200/JCO.2007.10.9777
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
J. Carver (2007)
10.1161/CIRCRESAHA.110.225003
Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics.
R. Gerszten (2011)
10.1016/j.jacc.2010.11.063
The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
N. Fallah-Rad (2011)
10.1200/JCO.2004.06.033
Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
O. Hequet (2004)
10.1016/j.hfc.2011.03.003
Newest echocardiographic techniques for the detection of cardiotoxicity and heart failure during chemotherapy.
Heloisa Sawaya (2011)
10.1038/bmt.2012.5
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation
N. Majhail (2012)
10.1200/JCO.2007.14.1242
Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.
D. Hershman (2008)
10.1016/j.tox.2007.12.006
Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity.
P. O'Brien (2008)
10.1016/j.cardfail.2010.04.004
HFSA 2010 Comprehensive Heart Failure Practice Guideline.
J. Lindenfeld (2010)
10.1093/eurjhf/hfr165
Detection, monitoring, and management of trastuzumab‐induced left ventricular dysfunction: an actual challenge
C. G. Tocchetti (2012)
10.1097/HP.0000000000000013
Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy
L. Travis (2014)
10.1097/CAD.0b013e3283394624
Anticancer therapy induced cardiotoxicity: review of the literature
S. Geiger (2010)
10.1200/JCO.1996.14.2.362
Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
L. Wexler (1996)
10.1136/bmj.b4606
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort
D. Mulrooney (2009)
Cardioprotective interventions for cancer patient receiving anthracyclines [serial online
EC van Dalen (2013)
10.1002/cncr.11274
Late anthracycline cardiotoxicity after childhood cancer
K. Sørensen (2003)
10.1002/cncr.24621
Cardiac toxicity associated with anthracycline‐containing chemotherapy in older women with breast cancer
X. Du (2009)
and Drug Administration (FDA)
US Foo (2012)
10.1158/1055-9965.EPI-11-0659
Role of Genetic Susceptibility in Development of Treatment-Related Adverse Outcomes in Cancer Survivors
S. Bhatia (2011)
Comprehensive Heart Failure Practice Guideline [serial online
America (2010)
Abstract 2942: High Mortality Rates are Associated with Withdrawal of Beta Blockers and Ace Inhibitors in Chemotherapy-Induced Heart Failure
Ashish Shukla (2008)
10.1016/J.CARDFAIL.2007.06.634
Superior Detection of Cardiotoxicity during Chemotherapy Using Biomarkers
D. Lenihan (2006)
10.1097/FPC.0b013e328301a869
Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity
L. Fan (2008)
Role of biomarkers in chemotherapyinduced cardiotoxicity
D Cardinale (2010)
10.1124/dmd.108.024711
Two Nonsynonymous Single Nucleotide Polymorphisms of Human Carbonyl Reductase 1 Demonstrate Reduced in Vitro Metabolism of Daunorubicin and Doxorubicin
Onkar S Bains (2009)
10.1158/1078-0432.CCR-07-1033
Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
B. Bird (2008)
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Cardiac Toxicity in Cancer Survivors/Lenihan et al Cancer
D A Mulrooney
10.1016/J.ECHO.2006.12.010
Reconstructed versus real-time 3-dimensional echocardiography: comparison with magnetic resonance imaging.
C. Jenkins (2007)
Role of 3-dimensional echocardiography in breast cancer: comparison with 2-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging
J Walker (2010)
10.1200/JCO.2006.10.4976
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
M. Pinder (2007)
10.1182/blood.v68.5.1114.1114
Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor.
M. Goldberg (1986)
10.1200/JCO.2004.11.032
Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline.
W. Landier (2004)
Neu / erbB2 amplification identifies a poor - prognosis group of women with node - negative breast cancer . Toronto Breast Cancer Study Group
MJ Piccart-Gebhart (1998)
10.1016/j.accreview.2004.02.013
Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy.
Matthew C. Hull (2003)
10.1093/ANNONC/MDH097
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
10.1200/JCO.2010.30.3404
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.
Steven E. Lipshultz (2012)
Genentech US BL 103792 supplement: Trastuzumab-Genentech I
10.1182/blood-2010-06-291328
Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation.
S. Galper (2011)
10.1007/s11906-010-0146-y
Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage
C. Geisberg (2010)
10.1093/JNCI/DJK064
Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.
M. Hooning (2007)
10.1200/JCO.1998.16.4.1340
neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.
I. Andrulis (1998)
10.1016/j.pcad.2010.06.002
The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society.
D. Lenihan (2010)
10.1634/theoncologist.2008-0137
Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.
M. Martín (2009)
10.1016/j.pcad.2010.04.002
Role of biomarkers in chemotherapy-induced cardiotoxicity.
D. Cardinale (2010)
10.7326/0003-4819-117-6-540_3
Heart Disease: A Textbook of Cardiovascular Medicine
E. Braunwald (1979)
10.1016/S1470-2045(10)70204-7
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
S. Lipshultz (2010)
10.1016/j.jacc.2012.08.1005
Progression of heart failure from AHA/ACC stage A to stage B or even C: can we all agree we should try to prevent this from happening?
D. Lenihan (2012)
10.1016/S0735-1097(00)00748-8
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy.
D. Cardinale (2000)
10.1056/NEJMOA060655
Sorafenib in advanced clear-cell renal-cell carcinoma.
B. Escudier (2007)
10.1016/j.ejca.2011.03.022
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.
Lynda M. Vrooman (2011)
10.1093/ANNONC/MDS293
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.
G. Curigliano (2012)
10.1016/j.jacc.2012.08.1000
Statins in preparation for chemotherapy: "do these medications help your fitness for battle?".
D. Lenihan (2012)
10.1182/blood-2009-06-229369
Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.
Can Sun (2010)
10.1016/j.jacc.2009.03.095
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
D. Cardinale (2010)
of Health and Human Services, National Institutes of Health, National Cancer Institute
US Departmen (2009)
10.1016/S1043-321X(99)92004-0
neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer
P. Ravdin (1999)
10.1182/blood-2011-06-358226
Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation.
S. Armenian (2011)
Sorafenib in advanced clearcell renal-cell carcinoma
B Escudier (2008)
10.1001/archinternmed.2010.233
Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study.
H. J. van der Pal (2010)
10.1200/JCO.2012.45.2938
Late cardiac effects of cancer treatment.
D. Lenihan (2012)
10.1124/pr.56.2.6
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
G. Minotti (2004)
10.1200/JCO.2007.15.6331
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
M. Schmidinger (2008)
10.1200/JCO.2009.26.7294
Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging.
J. Walker (2010)
10.1056/NEJMOA052122
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
E. H. Romond (2005)
10.1200/JCO.2005.02.4091
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
E. Tan-chiu (2005)
10.1200/JCO.2011.34.8987
Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
J. Blanco (2012)
10.1001/jama.2010.923
Long-term cause-specific mortality among survivors of childhood cancer.
R. Reulen (2010)
High mortality rates are associated with withdrawal of beta blockers and ACE inhibitors in chemotherapy-induced heart failure
A Shukla
10.1002/14651858.cd003917.pub2
Cardioprotective interventions for cancer patients receiving anthracyclines.
E. C. van Dalen (2005)
10.1056/NEJMOA052256
Trends in prevalence and outcome of heart failure with preserved ejection fraction.
Theophilus E Owan (2006)
10.1016/j.radonc.2011.10.017
Genetic variants in TGFβ-1 and PAI-1 as possible risk factors for cardiovascular disease after radiotherapy for breast cancer.
F. Hilbers (2012)
10.1016/j.pcad.2010.06.007
Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?
D. Sawyer (2010)
10.1016/J.EJCA.2007.06.024
111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
M. A. de Korte (2007)
Prevention of highdose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition
D Cardinale (2006)
10.1016/J.EHJ.2004.06.006
Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey.
M. Lenzen (2004)
10.1200/JCO.2007.14.8742
Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?
M. Ewer (2008)
and Drug Administration
US Foo (2013)
10.1093/jnci/djn206
New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
M. Ryberg (2008)
10.1200/JCO.2007.14.9401
Anthracycline cardiotoxicity: from bench to bedside.
L. Gianni (2008)
10.1016/j.breast.2010.02.001
Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery.
L. Murray (2010)
10.1056/NEJMOA052306
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
M. Piccart-Gebhart (2005)
10.1200/JCO.2010.34.3467
Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
H. Visscher (2012)
10.1093/eurjhf/hfq213
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
T. Eschenhagen (2011)
10.1016/j.cardfail.2011.10.015
Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.
L. Tarantini (2012)
10.1126/SCIENCE.2470152
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
D. Slamon (1989)
10.1016/S1470-2045(06)70724-0
Long-term follow-up of people who have survived cancer during childhood.
R. Skinner (2006)
High mortality rates are associated with withdrawal of beta blockers and ACE inhibitors in chemotherapy-induced heart failure [abstract
A Shukla (2008)
10.1038/nm.2919
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Sui Zhang (2012)
10.1158/1055-9965.EPI-09-0555
Cardiovascular Risk Factors in Adult Survivors of Pediatric Cancer—A Report from the Childhood Cancer Survivor Study
L. Meacham (2010)
10.1016/j.hfc.2011.03.002
Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy.
B. Ky (2011)
10.1200/JCO.2008.17.2627
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
M. Hensley (2009)
National Institutes of Health, National Cancer Institute
10.1002/14651858.CD005006.pub3
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
E. C. van Dalen (2006)
10.1093/JNCI/DJI067
Risk of cardiac death after adjuvant radiotherapy for breast cancer.
S. Giordano (2005)
10.1093/annonc/mdq200
Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines.
D. Bovelli (2010)
10.1093/ANNONC/MDR595
The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors.
E. Sieswerda (2012)
10.1161/CIRCULATIONAHA.106.635144
Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
D. Cardinale (2006)
10.1002/ijc.24147
Long‐term risk of cardiovascular disease in Hodgkin lymphoma survivors—Retrospective cohort analyses and a concept for prospective intervention
A. Andersson (2009)
10.1056/NEJMOA035153
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
S. Lipshultz (2004)
10.1016/S0735-1097(03)00759-9
Asymptomatic cardiac disease following mediastinal irradiation.
P. Heidenreich (2003)
10.1016/j.amjcard.2011.01.006
Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.
Heloisa Sawaya (2011)
10.1016/j.jacc.2013.05.019
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
C. Yancy (2013)
10.1186/1471-2407-10-337
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
L. Smith (2010)
10.1016/S0140-6736(07)60028-2
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
I. Smith (2007)
10.1038/sj.bjc.6604909
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring
A. Jones (2009)
10.1016/j.jacc.2012.07.068
Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
J. Chen (2012)
10.1097/01.COT.0000265629.30194.8E
Chronic health conditions in adult survivors of childhood cancer.
K. Oeffinger (2006)
10.1016/j.jacc.2010.07.023
Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
Geoffrey J. Yoon (2010)
Genetic variants in TGFbeta-1 and PAI-1 as possible risk factors for cardiovascular disease after radiotherapy for breast cancer
FS Hilbers (2010)
10.1200/JCO.2010.34.4309
Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
C. Richards (2011)
Comprehensive Heart Failure Practice Guideline
J Lindenfeld (2010)
10.1016/J.IJROBP.2006.08.071
Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data?
Susanne Schultz-Hector (2007)
Chapter 90 : Cardiovascular Complication of Cancer Therapeutic Agents
D Cardinale
10.1634/THEONCOLOGIST.8-SUPPL_2-17
Cardiac safety of liposomal anthracyclines.
T. Safra (2003)
10.2307/j.ctvzgb86t.9
Cancer
Zachary Hall (1906)
10.1016/J.BREAST.2003.09.002
Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.
T. Suter (2004)
10.1200/JCO.2004.03.516
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
E. Perez (2004)
10.1016/S1470-2045(09)70042-7
Cardiovascular toxicity caused by cancer treatment: strategies for early detection.
R. Altena (2009)
10.1161/01.CIR.0000130926.51766.CC
Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
D. Cardinale (2004)
10.1200/JCO.2009.27.3615
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.
D. Cardinale (2010)
10.1200/JCO.2004.06.022
Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines.
J. Silber (2004)
Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
I Smith (2007)
Cardiovascular Complication of Cancer Therapeutic Agents
D. Cardinale (2012)
10.6004/JNCCN.2011.0019
Trastuzumab-related cardiac dysfunction.
M. Telli (2011)
10.1161/CIRCRESAHA.110.224519
Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers.
M. Chen (2011)
10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K
Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia
C. Tan (1967)
10.1200/JCO.2005.02.3879
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
C. Tebbi (2007)
10.1200/JCO.2000.18.8.1725
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer.
M. T. Meinardi (2000)



This paper is referenced by
Outil de soutien aux survivantes du cancer du sein: Faciliter les soins de survie au cancer du sein à l’intention des médecins de famille et des patientes
Anna N Wilkinson (2020)
10.1016/j.ahj.2017.03.023
Electrocardiographic abnormalities and mortality in aging survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study
D. Mulrooney (2017)
Follow-up after treatment for breast cancer: Practical guide to survivorship care for family physicians.
J. Sisler (2016)
Cancer impacts microRNA expression, release and function in cardiac and skeletal muscle
D. Chen (2014)
Suivi après le traitement du cancer du sein: Guide pratique des soins aux survivantes à l’intention des médecins de famille
J. Sisler (2016)
10.1007/s11886-017-0873-7
Cardiovascular Risk in Survivors of Cancer
H. Zheng (2017)
10.2217/FCA.15.49
Multimodality assessment and treatment of chemotherapy-induced cardiotoxicity.
E. Storozynsky (2015)
10.1080/14737159.2017.1283219
Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy
D. Cardinale (2017)
10.1002/ejhf.654
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
J. Zamorano (2017)
10.1200/JCO.2014.56.1373
Individual prediction of heart failure among childhood cancer survivors.
E. Chow (2015)
10.1016/J.FMC.2015.03.027
Efectos adversos de la quimioterapia, las terapias dirigidas contra el cáncer y la hormonoterapia: ¿qué debe saber el médico de familia?
I. G. Lluis (2015)
10.1093/eurheartj/ehw211
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).
J. Zamorano (2016)
10.5603/KP.2016.0156
[2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines].
J. Zamorano (2016)
10.1016/j.ccl.2019.07.011
Arrhythmogenic Anticancer Drugs in Cardio-Oncology.
Isaac B Rhea (2019)
10.1007/s11886-016-0731-z
Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss
D. Cardinale (2016)
10.14232/phd.9757
Possibilities of early detection of cardiotoxicity in patients with malignancy
N. Csaba (2018)
Cancer AffectsmicroRNAExpression, Release, and Function in Cardiac and Skeletal Muscle
Daohong Chen (2014)
10.15744/2394-6504.3.105
The Use of Cardiac Resynchronization Therapy in Cancer Patients with Heart Failure.
Anecita Fadol (2017)
10.1007/978-3-319-16366-6_14
Prevention and Treatment of Cardiac Dysfunction in Breast Cancer Survivors.
C. Fabian (2015)
10.7748/CNP.2017.E1352
Mitigating risk of cardiovascular disease in people living with and beyond cancer
S. Faithfull (2017)
10.1080/14779072.2016.1239528
Chemotherapy-induced cardiotoxicity: importance of early detection
D. Cardinale (2016)
10.1188/19.ONF.104-112
Self-Management Support in Patients With Incurable Cancer: How Confident Are Nurses?
I. Jongerden (2019)
10.1016/j.ijnurstu.2015.09.001
Self-reported competence in long term care provision for adult cancer survivors: A cross sectional survey of nursing and allied health care professionals.
S. Faithfull (2016)
10.1158/0008-5472.CAN-13-2817
Cancer affects microRNA expression, release, and function in cardiac and skeletal muscle.
D. Chen (2014)
10.1007/978-3-319-64310-6_8
Cancer Survivorship in Adults.
C. Kiserud (2018)
10.1016/B978-0-12-802509-3.00037-6
Multidisciplinary Approach to Cardiac Disease in Cancer Patients
M. Galderisi (2017)
10.1161/JAHA.116.004653
Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy
K. Leger (2017)
Breast Cancer Survivorship Tool: Facilitating breast cancer survivorship care for family physicians and patients.
Anna N Wilkinson (2020)
10.1088/0031-9155/61/21/R344
Methodologies in the modeling of combined chemo-radiation treatments.
C. Grassberger (2016)
Tiled study design: using temporal overlap as a method to extend longitudinal follow-up among carefully selected time-limited cohorts
Name (2015)
10.1016/j.ejca.2018.06.017
Monitoring potentially modifiable lifestyle factors in cancer survivors: A narrative review on currently available methodologies and innovations for large-scale surveillance.
Jeroen W G Derksen (2018)
Reforzamiento intramiocárdico tardío en pacientes posquimioterapia
E. Alexánderson-Rosas (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar